Production of pharmaceutical proteins by transgenic animals

被引:186
作者
Houdebine, Louis-Marie [1 ]
机构
[1] INRA, Biol Dev & Reprod, F-78350 Jouy En Josas, France
关键词
Proteins; Recombinant; Pharmaceutical; Transgenic; Animals; Milk; Egg white; Monoclonal antibodies; Vaccines; RECOMBINANT PROTEINS; HUMAN-ERYTHROPOIETIN; HIGH-LEVEL; MILK; EXPRESSION; RABBITS; BIOREACTORS; ANTIBODY; PLANTS; GLYCOPROTEINS;
D O I
10.1016/j.cimid.2007.11.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Proteins started being used as pharmaceuticals in the 1920s with insulin extracted from pig pancreas. In the early 1980s, human insulin was prepared in recombinant bacteria and it is now used by all patients suffering from diabetes. Several other proteins and particularly human growth hormone are also prepared from bacteria. This success was limited by the fact that bacteria cannot synthesize complex proteins such as monoclonal antibodies or coagulation blood factors which must be matured by post-translational modifications to be active or stable in vivo. These modifications include mainly folding, cleavage, subunit association, gamma-carboxylation and glycosylation. They can be fully achieved only in mammalian cells which can be cultured in fermentors at an industrial scale or used in living animals. Several transgenic animal species can produce recombinant proteins but presently two systems started being implemented. The first is milk from farm transgenic mammals which has been studied for 20 years and which allowed a protein, human antithrombin III, to receive the agreement from EMEA (European Agency for the Evaluation of Medicinal Products) to be put on the market in 2006. The second system is chicken egg white which recently became more attractive after essential improvement of the methods used to generate transgenic birds. Two monoclonal antibodies and human interferon-beta 1a could be recovered from chicken egg white. A broad variety of recombinant proteins were produced experimentally by these systems and a few others. This includes monoclonal antibodies, vaccines, blood factors, hormones, growth factors, cytokines, enzymes, milk proteins, collagen, fibrinogen and others. Although these tools have not yet been optimized and are still being improved, a new era in the production of recombinant pharmaceutical proteins was initiated in 1987 and became a reality in 2006. In the present review, the efficiency of the different animal systems to produce pharmaceutical proteins are described and compared to others including plants and micro-organisms. (C) 2008 Elsevier Ltd. All fights reserved.
引用
收藏
页码:107 / 121
页数:15
相关论文
共 42 条
[1]   Plants as bioreactors:: A comparative study suggests that Medicago truncatula is a promising production system [J].
Abranches, R ;
Marcel, S ;
Arcalis, E ;
Altmann, F ;
Fevereiro, P ;
Stoger, E .
JOURNAL OF BIOTECHNOLOGY, 2005, 120 (01) :121-134
[2]   High level expression of tissue-nonspecific alkaline phosphatase in the milk of transgenic rabbits [J].
Bodrogi, L. ;
Brands, R. ;
Raaben, W. ;
Seinen, W. ;
Baranyi, M. ;
Fiechter, D. ;
Bosze, Zs .
TRANSGENIC RESEARCH, 2006, 15 (05) :627-636
[3]  
DITULLIO P, 1992, BIO-TECHNOL, V10, P74, DOI 10.1038/nbt0192-74
[4]   PROTEOLYTIC MATURATION OF PROTEIN-C UPON ENGINEERING THE MOUSE MAMMARY-GLAND TO EXPRESS FURIN [J].
DREWS, R ;
PALEYANDA, RK ;
LEE, TK ;
CHANG, RR ;
REHEMTULLA, A ;
KAUFMAN, RJ ;
DROHAN, WN ;
LUBON, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10462-10466
[5]   Making recombinant proteins in animals - different systems, different applications [J].
Dyck, MK ;
Lacroix, D ;
Pothier, F ;
Sirard, MA .
TRENDS IN BIOTECHNOLOGY, 2003, 21 (09) :394-399
[6]   Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin [J].
Edmunds, T ;
Van Patten, SM ;
Pollock, J ;
Hanson, E ;
Bernasconi, R ;
Higgins, E ;
Manavalan, P ;
Ziomek, C ;
Meade, H ;
McPherson, JM ;
Cole, ES .
BLOOD, 1998, 91 (12) :4561-4571
[7]  
GIERSING B, 2006, BIOFORUM EUROPE, V34
[8]   The potential benefits of insulators on heterologous constructs in transgenic animals [J].
Giraldo, P ;
Rival-Gervier, S ;
Houdebine, LM ;
Montoliu, L .
TRANSGENIC RESEARCH, 2003, 12 (06) :751-755
[9]   Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors [J].
Giritch, Anatoli ;
Marillonnet, Sylvestre ;
Engler, Carola ;
van Eldik, Gerben ;
Botterman, Johan ;
Klimyuk, Victor ;
Gleba, Yuri .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (40) :14701-14706
[10]   Biopharmaceutical production in plants: problems, solutions and opportunities [J].
Gomord, W ;
Chamberlain, P ;
Jefferis, R ;
Faye, L .
TRENDS IN BIOTECHNOLOGY, 2005, 23 (11) :559-565